Paras Healthcare IPO 2026: GMP Today, Day 1 Subscription, Price Band and Hospital Business

Paras Healthcare IPO 2026: Latest Update

Paras Healthcare Limited has opened its mainboard IPO on October 21, 2026, bringing one of India's growing hospital chains to the public market. The company operates under the Paras Health brand and provides specialised medical services across several regions of India.

The company aims to raise ₹1,450 crore through a combination of a ₹500 crore fresh issue and a ₹950 crore offer for sale by existing shareholders. The IPO will close on October 23, 2026, and the shares are expected to list on the BSE and NSE on October 28.

Investors are watching the issue for its hospital expansion potential, financial performance, debt-reduction plans and the movement in its unofficial grey market premium.

Paras Healthcare IPO Details

The fresh issue will provide funds to the company for specified financial objectives. The proceeds from the offer for sale, after applicable expenses and taxes, will go to the selling shareholders rather than the company.

Paras Healthcare IPO GMP Today

The grey market premium for Paras Healthcare IPO was reported at approximately ₹50 per share on October 21 by Financial Express. Other grey-market trackers showed higher estimates, illustrating that these unofficial quotes can vary by source and time.

Using ₹50 as an illustrative GMP and ₹693 as the upper price band, the estimated price would be ₹743 per share.

GMP is not an official exchange price and does not guarantee listing gains. It can move during the subscription period, so the latest figure should be checked before publication.

Paras Healthcare IPO Day 1 Subscription Status

The IPO opened for public subscription on October 21, 2026. Final Day 1 category-wise subscription figures were not confirmed in the sources available for this update.

Investors can monitor the subscription levels of qualified institutional buyers (QIBs), non-institutional investors (NIIs) and retail investors as bidding progresses. The final subscription status will provide a clearer picture of demand across investor categories.

Anchor investors reportedly contributed approximately ₹625.5 crore ahead of the public issue. Anchor participation is separate from the subscription figures for public investors and should not be treated as the final overall subscription result.

About Paras Healthcare Limited

Paras Healthcare is a hospital operator providing tertiary and quaternary healthcare services through its Paras Health network. Its business focuses on specialised medical treatment, complex procedures, diagnostics, inpatient care and critical-care services.

As of June 30, 2026, the company operated eight hospitals with a combined capacity of 2,211 beds. Its hospitals are located in Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi and Srinagar.

The company serves patients across North India and eastern India, including markets where access to advanced specialist treatment can be an important consideration for patients and families.

Paras Healthcare Hospital Network and Medical Specialities

Paras Healthcare focuses on several clinical disciplines, including cardiac sciences, oncology, neurosciences, gastroenterology, orthopaedics, sports injury treatment and renal sciences.

These specialities require experienced medical professionals, advanced equipment, diagnostic facilities and coordinated patient-care systems. The company's ability to attract doctors, maintain treatment quality and use its hospital capacity efficiently is important to its long-term performance.

The hospital network also provides opportunities to develop services in existing locations and improve the utilisation of available beds and medical infrastructure.

Paras Healthcare IPO Financial Performance

Paras Healthcare's financial performance should be assessed alongside its debt position, hospital occupancy, capital expenditure and operating cash flow.

According to IPO-related financial data, the company reported revenue of approximately ₹1,605.95 crore and profit after tax of ₹43.83 crore for the reported financial period. Investors should refer to the final prospectus for the complete audited financial comparison across FY2024, FY2025 and FY2026.

The company reported a bed occupancy rate of 61.75% in FY2026, compared with 50.78% in FY2025 and 52.46% in FY2024. Higher occupancy can improve the utilisation of hospital infrastructure, although future performance depends on patient demand, operating costs and the availability of medical specialists.

As of August 31, 2026, the company and its subsidiaries had aggregate secured borrowings of approximately ₹990.33 crore. This makes financing costs and debt management important factors for investors to consider.

Paras Healthcare IPO Objectives

The fresh issue proceeds are intended for repayment or prepayment of certain outstanding borrowings, investment in its wholly owned subsidiary Plus Medicare Hospitals Private Limited (PMHPL) to support repayment of its borrowings, and general corporate purposes.

The offer documents identify approximately ₹320.90 crore for repayment or prepayment of certain company borrowings and ₹54.10 crore for investment in PMHPL for debt repayment or prepayment.

Reducing debt may help improve financial flexibility, but hospital operators also need funds for equipment, maintenance, staffing and future expansion. Investors should consider the intended use of proceeds alongside the company's broader capital requirements.

Paras Healthcare IPO Growth Opportunities

India's healthcare sector has demand for specialised treatment, modern diagnostic services and hospital infrastructure. Paras Healthcare's presence across multiple states gives it access to regional markets beyond India's largest metropolitan centres.

Its specialised clinical services may support patient referrals and demand for complex treatments. Improvements in bed occupancy and efficient use of existing infrastructure could also support operating performance.

However, hospital expansion requires significant investment and depends on recruiting medical professionals, maintaining service quality, obtaining regulatory approvals and managing operating costs.

Paras Healthcare IPO Risks

Investors should consider the following risks before applying:

• Debt obligations: Borrowings can increase interest expenses and pressure cash flow.

• Hospital occupancy: Lower patient volumes can affect revenue while fixed operating costs continue.

• Competition: Hospitals compete for doctors, patients, insurance partnerships and specialised services.

• Capital expenditure: Medical equipment and hospital infrastructure require ongoing investment.

• Regulatory exposure: Healthcare operations are subject to clinical, licensing and compliance requirements.

• Litigation and contingent liabilities: Disputes and guarantees disclosed in the offer documents may create financial or operational uncertainty.

Investors should review the risk factors in the Red Herring Prospectus rather than relying only on the company's growth story.

Paras Healthcare IPO Important Dates

These dates reflect the announced schedule and may be subject to official exchange updates.

Paras Healthcare IPO: Key Points for Investors

Paras Healthcare IPO combines a fresh capital raise with an offer for sale by existing shareholders. Its eight-hospital network, specialised treatment services and improving FY2026 bed occupancy are important aspects of the business.

At the same time, investors should assess debt, operating margins, hospital utilisation, valuation and disclosed contingent liabilities. Subscription data and GMP may provide additional market context, but neither guarantees a positive listing.

Paras Healthcare IPO Summary

Paras Healthcare IPO opened on October 21 and will close on October 23, 2026. The company is raising ₹1,450 crore at ₹660–₹693 per share through a ₹500 crore fresh issue and a ₹950 crore offer for sale.

With eight hospitals and 2,211 beds as of June 30, 2026, the company provides specialised healthcare services across several regions of India. The IPO proceeds will primarily support debt repayment and investment in its subsidiary.

The shares are expected to list on October 28, 2026. Investors should check updated GMP and final subscription figures and evaluate the company's financials, debt and risks before making an application decision.